HRA pharma has announced the resignation of David Wright who moves on after serving the company for more than five years as chief executive officer.
The company has appointed Martyn Hilton, chief commercial officer for HRA Pharma, as interim CEO effective from September 1, 2022.
David helmed the company during a period of transformation and set the course for its tremendous growth, elevating HRA Pharma into a leading provider of over-the-counter self-care products.
He commented: “Given the significant progress HRA has made, along with my personal goals after leading HRA for more than five years, I believe now is the time to step away from the business.
“I am proud of all that we have accomplished, making HRA well-known for its Women’s Health, Wound Care and Scar Care leadership, operating via brands including ellaOne, Hana, Compeed and Mederma. I appreciate all the team members involved in the success of the organization and believe Perrigo and HRA are well-positioned to elevate this business and these brands to the next level.”
Founded in 1996, HRA Pharma is a Perrigo company and one of the fastest growing
consumer healthcare businesses in the world which focuses on prescription to
over-the-counter switches.
Incoming interim CEO Martyn Hilton said: “I am honoured for the opportunity to lead such a great team at this exciting time in its history. I look forward to progressing the smooth integration already underway with Perrigo while also advancing our purposeful self-care vision. I would like to thank David for his incredible leadership over the years and wish him the best in his future endeavours.”
